<DOC>
	<DOCNO>NCT01731119</DOCNO>
	<brief_summary>The overarch purpose pilot study collect preliminary data regard variability weight gain associate lurasidone ( Latuda© ) treatment antipsychotic naive child adolescent order inform decision include lurasidone arm future large scale trial different approach minimize antipsychotic associate weight gain pediatric population . In adult , lurasidone appear cause minimal weight gain . The participant 6-19 year old psychotic spectrum , mood spectrum , autism spectrum disorder . They 4 week less lifetime antipsychotic exposure .</brief_summary>
	<brief_title>Study Lurasidone Treating Antipsychotic Naive Quasi-Naive Children Adolescents</brief_title>
	<detailed_description>This multi-site , 12-week , open-label study assess weight metabolic change associate lurasidone treatment . Antipsychotic naive subject start open-label treatment follow flexible titration schedule . Quasi-antipsychotic naive subject ( less 4 week total AP treatment ) start lurasidone taper antipsychotic estimate 4 week depend dose tolerability prior antipsychotic . Other psychoactive medication include antidepressant , benzodiazepine , stimulant , alpha-2 agonist , mood stabilizer allow long dose change , unless clinically necessary . Assessments weight , efficacy , side effect conduct baseline , week 2 , week 4 , week 8 , week 12 . The primary outcome percent change weight . The secondary outcome include psychiatric efficacy measure side effect .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Mood Disorders</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Asperger Syndrome</mesh_term>
	<mesh_term>Developmental Disabilities</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Male female child adolescents 6 19 year age race ethnicity Subject must meet DSMIVTR criterion psychotic spectrum , mood spectrum autism spectrum disorder define one follow diagnosis : schizophrenia ( type ) schizoaffective disorder schizophreniform disorder psychosis NOS autistic disorder significant irritability/aggression ( ABCC Irritability subscale score great equal 18 ) Asperger syndrome significant irritability/aggression ( ABCC Irritability subscale score great equal 18 ) pervasive developmental disorder NOS significant irritability/aggression ( ABCC Irritability subscale score great equal 18 ) bipolar type I bipolar type II mood disorder NOS major depression psychotic feature major depression ( unresponsive 2 different antidepressant ) severe mood dysregulation ( SMD ) accord Leibenluft colleague broad spectrum bipolar disorder Subjects must ≤ 4 week lifetime exposure antipsychotic medication dosage . These medication include olanzapine ( Zyprexa© ) , quetiapine ( Seroquel© ) , risperidone ( Risperdal© ) , ziprasidone ( Geodon© ) , aripiprazole ( Abilify© ) , asenapine ( Saphris© ) , iloperidone ( Fanapt© ) , lurasidone ( Latuda© ) , haloperidol , chlorpromazine , perphenazine , fluphenazine , thiothixene , clozapine Subjects psychoactive medication ask change dose medication course study unless clinically necessary Sexually active girl must agree use two effective form birth control ( i.e . hormonal spermicidal barrier ) abstinent ) Primary caretaker able participate study appointment clinically indicate Ability child participate aspect protocol per investigator 's clinical judgment After consider aspect study participation subject ( adult ) subject 's parent LAR must consent participation After consider aspect study participation , subject must assent participation developmentally appropriate obtain assent Based current lifetime DSMIVTR criterion , diagnosis Eating Disorder ( Anorexia Nervosa Bulimia Nervosa ) Based DSMIVTR criterion , diagnosis Substance Dependence Disorder ( tobacco dependence ) within past month Treatment follow concomitant medication : strong CYP3A4 inhibitor ( ex : Ketoconazole ) , strong CYP3A4 inducer ( ex : Rifampin ) Current past treatment lurasidone ( Latuda© ) result nonresponse intolerance Females pregnant breastfeeding Ongoing previously undisclosed child abuse require new department social service intervention Subjects , Investigator 's opinion , might suitable study</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Latuda , lurasidone , antipsychotic , autism , mood , psychosis</keyword>
</DOC>